ES2482192T3 - Vacunación intradérmica del péptido de HPV - Google Patents

Vacunación intradérmica del péptido de HPV Download PDF

Info

Publication number
ES2482192T3
ES2482192T3 ES08753797.3T ES08753797T ES2482192T3 ES 2482192 T3 ES2482192 T3 ES 2482192T3 ES 08753797 T ES08753797 T ES 08753797T ES 2482192 T3 ES2482192 T3 ES 2482192T3
Authority
ES
Spain
Prior art keywords
hpv
cancer
peptide
medicament
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08753797.3T
Other languages
English (en)
Spanish (es)
Inventor
Sjoerd Henricus Van Der Burg
Gemma G. Kenter
Cornelis Johannes Maria Melief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leiden University Medical Center
Original Assignee
Leiden University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiden University Medical Center filed Critical Leiden University Medical Center
Application granted granted Critical
Publication of ES2482192T3 publication Critical patent/ES2482192T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ES08753797.3T 2007-05-31 2008-05-27 Vacunación intradérmica del péptido de HPV Active ES2482192T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94107007P 2007-05-31 2007-05-31
EP07109287 2007-05-31
US941070P 2007-05-31
EP07109287 2007-05-31
PCT/NL2008/050315 WO2009002159A2 (en) 2007-05-31 2008-05-27 Intradermal hpv peptide vaccination

Publications (1)

Publication Number Publication Date
ES2482192T3 true ES2482192T3 (es) 2014-08-01

Family

ID=38477016

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08753797.3T Active ES2482192T3 (es) 2007-05-31 2008-05-27 Vacunación intradérmica del péptido de HPV

Country Status (10)

Country Link
US (2) US9562075B2 (enExample)
EP (1) EP2155240B1 (enExample)
JP (2) JP2010530362A (enExample)
CN (1) CN101795705A (enExample)
AU (1) AU2008269721B2 (enExample)
BR (1) BRPI0812311A8 (enExample)
CA (1) CA2688589A1 (enExample)
ES (1) ES2482192T3 (enExample)
MX (1) MX2009012922A (enExample)
WO (1) WO2009002159A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468763B1 (en) * 2007-05-31 2014-06-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
JP5707326B2 (ja) * 2008-09-02 2015-04-30 アンティジェン・エクスプレス・インコーポレーテッドＡｎｔｉｇｅｎ Ｅｘｐｒｅｓｓ，Ｉｎｃ． ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法
JP6069212B2 (ja) 2010-12-02 2017-02-01 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ ペプチド骨格設計
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
JP7092662B2 (ja) 2015-10-30 2022-06-28 チルドレンズ ナショナル メディカル センター ナイーブｔ細胞集団からのｈｐｖ抗原特異的ｔ細胞の生成
US11160861B2 (en) 2015-11-18 2021-11-02 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyI:C polynucleotide adjuvant and a lipid-based adjuvant
CN117018170A (zh) 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
US11524063B2 (en) * 2017-11-15 2022-12-13 Arizona Board Of Regents On Behalf Of Arizona State University Materials and methods relating to immunogenic epitopes from human papillomavirus
MA52003A (fr) * 2018-03-12 2021-01-20 Sqz Biotechnologies Co Procédés de traitement de maladies associées au hpv
BR112020018612A2 (pt) * 2018-03-12 2020-12-29 Sqz Biotechnologies Company Entrega intracelular de biomoléculas para modificar a resposta imune
EP3784688A2 (en) * 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
JP2024503277A (ja) * 2020-12-29 2024-01-25 スクイーズ バイオテクノロジーズ カンパニー 活性化抗原担体の製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5932412A (en) 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
DE9106105U1 (de) * 1991-05-17 1991-11-07 Behringwerke Ag, 3550 Marburg Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
WO1997023237A1 (en) 1995-12-22 1997-07-03 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
WO1999061065A1 (en) 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6641994B2 (en) * 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ES2724121T3 (es) * 2000-12-08 2019-09-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
EP1417353A4 (en) * 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
US6884605B2 (en) * 2001-08-09 2005-04-26 Board Of Trustees Of The University Of Arkansas Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
EP1708745B1 (en) 2003-12-23 2012-04-18 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
CN101189014A (zh) * 2005-04-27 2008-05-28 莱顿大学医学中心 用于治疗hpv诱导的上皮内瘤样病变的方法和手段
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Also Published As

Publication number Publication date
US20170143818A1 (en) 2017-05-25
AU2008269721A1 (en) 2008-12-31
BRPI0812311A8 (pt) 2019-02-05
BRPI0812311A2 (pt) 2014-10-29
CA2688589A1 (en) 2008-12-31
US9562075B2 (en) 2017-02-07
AU2008269721B2 (en) 2013-01-10
EP2155240A2 (en) 2010-02-24
JP5888823B2 (ja) 2016-03-22
WO2009002159A3 (en) 2009-02-12
WO2009002159A2 (en) 2008-12-31
MX2009012922A (es) 2010-07-05
JP2010530362A (ja) 2010-09-09
CN101795705A (zh) 2010-08-04
JP2014185179A (ja) 2014-10-02
EP2155240B1 (en) 2014-04-30
US20100196353A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
US11458198B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
EP2155240B1 (en) Intradermal hpv peptide vaccination
ES2519043T3 (es) Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
ES2746979T3 (es) Epítopos de HPV a los que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas
AU2013205259B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
AU2017202609B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
HK40019593A (en) Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines